Publications by authors named "Luisa Maria Botella"

Claim this Profile
N
N-acetylcysteine and raloxifene boost photodynamic therapy against cutaneous squamous cell carcinoma by decreasing TGFβ1 secreted by cancer-associated fibroblasts.
María Gallego-Rentero, Luisa María Botella, Marta Mascaraque, Jimena Nicolás-Morala, Virginia Albiñana

Int J Biol Sci· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exceptional Evolution of a Squamous Odontogenic Tumor in the Jaw: Molecular Approach.
Miguel Alonso-Juarranz, Oscar De La Sen, Pablo Pérez, Maria Aranzazu González-Corchón, Santiago Cabezas-Camarero, Luisa María Botella

Int J Mol Sci· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and Cellular Characterization of Primary Endothelial Cells from a Familial Cavernomatosis Patient.
Laura Lorente-Herraiz, Angel M Cuesta, Jaime Granado, Lucía Recio-Poveda, Luisa-María Botella

Int J Mol Sci· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tacrolimus as a Promising Drug for Epistaxis and Gastrointestinal Bleeding in HHT.
Paloma Álvarez-Hernández, José Luis Patier, Sol Marcos, Vicente Gómez Del Olmo, Laura Lorente-Herraiz, Luisa María Botella

J Clin Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Propranolol: A "Pick and Roll" Team Player in Benign Tumors and Cancer Therapies.
Virginia Albiñana, Eunate Gallardo-Vara, Juan Casado-Vela, Lucía Recio-Poveda, Luisa María Botella

J Clin Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Splicing Mutation in the Gene as a Cause of HHT2.
Suriel Errasti Díaz, Mercedes Peñalva, Lucía Recio-Poveda, Susana Vilches, Juan Casado-Vela, Luisa María Botella

J Clin Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases.
Angel M Cuesta, Eunate Gallardo-Vara, Juan Casado-Vela, Lucía Recio-Poveda, Luisa-María Botella

Int J Mol Sci· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blockade of β2-Adrenergic Receptor Reduces Inflammation and Oxidative Stress in Clear Cell Renal Cell Carcinoma.
Virginia Albiñana, Lucía Recio-Poveda, Pilar González-Peramato, Luis Martinez-Piñeiro, Luisa María Botella

Int J Mol Sci· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds.
Sol Marcos, Luisa María Botella, Virginia Albiñana, Agustina Arbia, Anna María de Rosales

J Clin Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Exosomal MicroRNA Signature by Liquid Biopsy in Hereditary Hemorrhagic Telangiectasia Patients.
Ana Pozo-Agundo, Nerea Villaescusa, Jordi Martorell-Marugán, Olga Soriano, Socorro Leyva, Luisa María Botella

Int J Mol Sci· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
eHealth for patients with rare diseases: the eHealth Working Group of the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN).
Alessia Paglialonga, Raffaella Gaetano, Leema Robert, Marine Hurard, Luisa Maria Botella

Orphanet J Rare Dis· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 Infection in Hereditary Hemorrhagic Telangiectasia Patients Suggests Less Clinical Impact Than in the General Population.
Sol Marcos, Virginia Albiñana, Lucia Recio-Poveda, Belisa Tarazona, María Patrocinio Verde-González, Luisa-María Botella

J Clin Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Raloxifene and n-Acetylcysteine Ameliorate TGF-Signalling in Fibroblasts from Patients with Recessive Dominant Epidermolysis Bullosa.
Tania Aguado, Marta García, Adela García, Gemma Ferrer-Mayorga, Lucía Martínez-Santamaría, Luisa-María Botella

Cells· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel-Lindau Disease.
Virginia Albiñana, Eunate Gallardo-Vara, Isabel de Rojas-P, Lucia Recio-Poveda, Tania Aguado, Luisa Maria Botella

J Clin Med· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CLN5 in heterozygosis may protect against the development of tumors in a VHL patient.
Isabel de Rojas-P, Virginia Albiñana, Lucía Recio-Poveda, Amanda Rodriguez-Rufián, Ángel M Cuesta, Luisa-María Botella

Orphanet J Rare Dis· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding.
Virginia Albiñana, Angel M Cuesta, Isabel de Rojas-P, Eunate Gallardo-Vara, Lucía Recio-Poveda, Luisa María Botella

J Clin Med· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
11PS04 is a new chemical entity identified by microRNA-based biosensing with promising therapeutic potential against cancer stem cells.
Tania Aguado, José A Romero-Revilla, Rosario Granados, Susana Campuzano, Rebeca M Torrente-Rodríguez, Luisa María Botella

Sci Rep· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topically Applied Etamsylate: A New Orphan Drug for HHT-Derived Epistaxis (Antiangiogenesis through FGF Pathway Inhibition).
Virginia Albiñana, Guillermo Giménez-Gallego, Angela García-Mato, Patricia Palacios, Lucia Recio-Poveda, Luisa-María Botella

TH Open· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.
Elisabetta Buscarini, Luisa Maria Botella, Urban Geisthoff, Anette D Kjeldsen, Hans Jurgen Mager

Orphanet J Rare Dis· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Propranolol increases the therapeutic response to temozolomide in a patient with metastatic paraganglioma.
Miguel-Angel Díaz-Castellanos, Karina Villar Gómez de Las Heras, Tamara Díaz-Redondo, Encarnación González-Flores, Virginia Albiñana, Luisa-María Botella

F1000Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease.
Virginia Albiñana, Rosa María Jiménez Escribano, Isabel Soler, Luis Rodríguez Padial, Lucia Recio-Poveda, Luisa María Botella

Orphanet J Rare Dis· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT).
Roberto Zarrabeitia, Concepción Fariñas-Álvarez, Miguel Santibáñez, Blanca Señaris, Ana Fontalba, Luisa María Botella

Health Qual Life Outcomes· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients.
Virginia Albiñana, Karina Villar Gómez de Las Heras, Gemma Serrano-Heras, Tomás Segura, Ana Belén Perona-Moratalla, Luisa María Botella

Orphanet J Rare Dis· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Research on potential biomarkers in hereditary hemorrhagic telangiectasia.
Luisa-María Botella, Virginia Albiñana, Luisa Ojeda-Fernandez, Lucia Recio-Poveda, Carmelo Bernabéu

Front Genet· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MiR-205 is downregulated in hereditary hemorrhagic telangiectasia and impairs TGF-beta signaling pathways in endothelial cells.
Sebastien P Tabruyn, Sylvain Hansen, Maria-Luisa Ojeda-Fernández, Nicolas Bovy, Roberto Zarrabeitia, Luisa-Maria Botella

Angiogenesis· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis